Literature DB >> 27174077

How should we approach Aspergillus in lung secretions of patients with COPD?

J Barberán1, F J Candel, A Arribi.   

Abstract

Aspergillus spp. is frequently isolated in respiratory samples from patients with severe COPD; however, the clinical significance of this mold is unclear and its presence may indicate temporary passage, benign chronic carriage, or onset of invasive disease. The definitive diagnosis of pulmonary aspergillosis in COPD patients is often difficult owing to the lack of specific clinical and radiological signs. However, retrospective studies show the risk for developing pulmonary aspergillosis in older patients with severe COPD, and a high number of comorbidities who have received treatment with corticosteroids and/or broad spectrum antibioties. The development of algorithms based on microbiological and radiological data and risk factors for pulmonary aspergillosis can help to differentiate between colonization and infection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27174077

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  4 in total

1.  Improving diagnostic accuracy for invasive pulmonary aspergillosis in the intensive care unit.

Authors:  Katerina Kaziani; Elli Mitrakou; George Dimopoulos
Journal:  Ann Transl Med       Date:  2016-09

2.  Assessing Differences between Clinical Isolates of Aspergillus fumigatus from Cases of Proven Invasive Aspergillosis and Colonizing Isolates with Respect to Phenotype (Virulence in Tenebrio molitor Larvae) and Genotype.

Authors:  Sam El-Kamand; Martina Steiner; Carl Ramirez; Catriona Halliday; Sharon C-A Chen; Alexie Papanicolaou; Charles Oliver Morton
Journal:  Pathogens       Date:  2022-03-31

3.  Rapidly progressing dual infection with Aspergillus and Rhizopus: when soil inhabitants become deadly invaders.

Authors:  Milind Bhagat; Alwyn Rapose
Journal:  BMJ Case Rep       Date:  2016-12-08

4.  [Integral approach to the acute exacerbation of chronic obstructive pulmonary disease].

Authors:  J González Del Castillo; F J Candel; J de la Fuente; F Gordo; F J Martín-Sánchez; R Menéndez; A Mujal; J Barberán
Journal:  Rev Esp Quimioter       Date:  2018-10-04       Impact factor: 1.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.